GlassScriptPhysician profile
Lauren I Krzos
NPI 1689203606
$14,182.15
in general payments reported to CMS, 2019-2025
28 companies · $2,539 in 2025
The $2,539 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,892 · 2023: $4,295 · 2024: $4,457 · 2025: $2,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,155.02 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,993.83 | 2022-2025 | Tavneos, Evenity, Prolia |
| Abbvie INC. | $2,028.82 | 2022-2025 | |
| Janssen Biotech, INC. | $1,575.21 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Ucb, INC. | $1,557.30 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $1,295.57 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $648.91 | 2022-2025 | Saphnelo, Andexxa, Flumist Quadrivalent |
| Pfizer INC. | $579.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $548.38 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.97 | 2022-2025 | Cyltezo, Ofev, Spevigo |
| Radius Health, INC. | $425.74 | 2022-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $418.93 | 2022-2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $277.23 | 2023-2025 | Benlysta |
| Genentech USA, INC. | $170.94 | 2023-2025 | Actemra |
| Fresenius Kabi USA, LLC | $151.23 | 2023-2024 | Idacio |
| Scilex Pharmaceuticals INC. | $145.57 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $142.73 | 2022-2024 | Gelsyn-3, Supartz Fx Sodium Hyaluronate |
| Aurinia Pharma U.S., INC. | $137.36 | 2022-2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $131.30 | 2025 | Tremfya |
| Depuy Synthes Sales INC. | $126.98 | 2023-2025 | Orthovisc, Monovisc |
| Horizon Therapeutics Plc | $119.03 | 2022 | |
| Alexion Pharmaceuticals, INC. | $63.17 | 2024 | Strensiq |
| Lilly USA, LLC | $49.04 | 2024 | Taltz, Zepbound |
| Ferring Pharmaceuticals INC. | $42.13 | 2022-2024 | Euflexxa |
| Invivyd INC | $33.74 | 2025 | Pemgarda |
| Octapharma USA, INC. | $31.16 | 2025 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $21.70 | 2023 | |
| Shorla Oncology INC. | $19.27 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $18.10 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Krzos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.